Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens

(2014) Atsushi Ogata et al.   Modern Rheumatology

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

(2013) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

(2012) Edward Clark Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

(2012) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability

(2012) M. Fallahi-Sichani et al.   JOURNAL OF IMMUNOLOGY

Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)

(2012) Mamoudou Maiga et al.   JOURNAL OF INFECTIOUS DISEASES

Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy

(2012) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study

(2012) Peter Nash et al.   ARTHRITIS CARE & RESEARCH

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)

(2011) Jeffrey Kaine et al.   ANNALS OF THE RHEUMATIC DISEASES

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

(2011) Asta Baranauskaite et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

(2011) M. Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes

(2011) J. Bathon et al.   ANNALS OF THE RHEUMATIC DISEASES

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

(2011) Sanna Rosengren et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

(2011) J. M. Kremer et al.   ANNALS OF THE RHEUMATIC DISEASES

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis

(2011) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study

(2011) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

(2011) R. F. van Vollenhoven et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

(2011) D L Scott   CLINICAL PHARMACOLOGY & THERAPEUTICS

The risk of tuberculosis in patients treated with TNF antagonists

(2011) Eva Salgado et al.   Expert Review of Clinical Immunology

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Cytokine blockade in inflammatory bowel diseases

(2011) Clémentine Perrier et al.   Immunotherapy

Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies

(2011) Walter Reinisch et al.   INFLAMMATORY BOWEL DISEASES

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis

(2011) EDWARD C. KEYSTONE et al.   JOURNAL OF RHEUMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

(2011) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

(2011) X. Baraliakos et al.   RHEUMATOLOGY

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

(2010) E. Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

(2010) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

(2010) I. Solovic et al.   EUROPEAN RESPIRATORY JOURNAL

Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER

(2010) D. van der HEIJDE et al.   JOURNAL OF RHEUMATOLOGY

A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis

(2010) R. D. INMAN et al.   JOURNAL OF RHEUMATOLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of latent tuberculosis infection: An update

(2010) Philip LOBUE et al.   RESPIROLOGY

A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries

(2010) Jeffrey R. Curtis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

(2009) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada

(2009) Paul Brassard et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

(2009) F. Tubach et al.   ARTHRITIS AND RHEUMATISM

Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis

(2009) Nick Bansback et al.   DERMATOLOGY

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

(2009) Alessandro Liberati et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis

(2009) Der-Yuan Chen et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis

(2009) Margaret H. Y. Ma et al.   RHEUMATOLOGY

European biologicals registers: methodology, selected results and perspectives

(2008) A Zink et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study

(2008) B Combe et al.   ANNALS OF THE RHEUMATIC DISEASES

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

(2008) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

(2008) Victoria Bejarano et al.   ARTHRITIS AND RHEUMATISM

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

(2008) Jonathan Kay et al.   ARTHRITIS AND RHEUMATISM

A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China

(2008) Dawei Hu et al.   RHEUMATOLOGY INTERNATIONAL

Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review

(2007) Alma Tostmann et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY